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Child neurodevelopmental disorders such as attention deficit hyperactivity disorder (ADHD), autism 
spectrum disorder (ASD) and intellectual disability (ID) typically are complex, heterogeneous, 
conditions that show considerable clinical overlap. There are both genetic and environmental 
contributions to their aetiology, which are not yet fully elucidated. However, immense progress has 
been made in our understanding of their genetic basis in the last two decades. This short review aims 
to synthesise the key findings in this regard, with a focus on some of the factors that are most relevant 
to clinical practice. 
Family and twin studies provided the first evidence of the familial aggregation and heritability of child 
neurodevelopmental disorders. For example, the heritability estimate for ADHD is 88%[1] and for ASD 
it is 64-91%[2]. Families often want to know the likelihood of having a child with a 
neurodevelopmental problem in future if they themselves or their offspring have a 
neurodevelopmental disorder. First degree relatives of people with ADHD have a five to ninefold 
elevated risk of having ADHD themselves,[3] and siblings of those with ASD are estimated to have a 
tenfold elevated risk of having ASD[4]. Family studies also show shared genetic effects across 
disorders,[5] i.e. siblings of a person with one disorder (e.g. ADHD) are themselves at elevated risk of 
both that disorder and other neurodevelopmental conditions (e.g. ASD, reading disability), as well as 
of subthreshold traits.[6, 7]. These factors mean that parents of children with a neurodevelopmental 
disorder may show elevated levels of neurodevelopmental traits that do not necessarily meet criteria 
for a diagnosed disorder. These characteristics could impact on clinical assessment and parental ability 
to implement interventions. 
What genetic factors contribute to this high heritability? Both common (single nucleotide 
polymorphisms, SNPs, >5% population frequency) and rare (<1%) genetic variants, which can be 
inherited or arise de novo in offspring, are involved in the pathogenesis of ADHD, ASD and ID. Early 
work into the genetic basis of neurodevelopmental disorders used linkage analysis to identify 
relatively high-penetrance variants associated with neurodevelopmental disorders by studying large 
pedigrees of affected families. Another early approach investigated candidate genes, selected based 
on their hypothesised role in the underlying biology of the disorder (e.g. dopamine receptor genes in 
ADHD). Both approaches however, have significant disadvantages and these studies, on the whole, 
failed to produce consistent, reproducible results. They have been superseded by genome-wide 
platforms that allow comparison between large samples of patients and controls to identify 
differences in genetic make-up without any a priori hypotheses about genetic susceptibility loci. 
Genome-wide association studies (GWAS), have so far been successful in identifying multiple common 
genetic risk variants for adult-onset disorders such as schizophrenia,[8] bipolar disorder[9] and many 
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physical illnesses such as diabetes [10]. GWAS of child neurodevelopmental disorders have somewhat 
lagged behind, not least because of the difficulty accumulating large samples of patients with these 
disorders although genome-wide significant findings have now emerged for both ADHD[11] and 
ASD[12]. Such findings are being used to investigate the biology and epidemiology of these disorders. 
Nevertheless available evidence suggests that the individual effect size of any given individual 
common gene variant is small, and that the genetic architecture of neurodevelopmental disorders, 
like other complex diseases, is explained by multiple common gene variants that have pleiotropic 
effects (i.e. they confer risk for various phenotypes) on multiple neuropsychiatric disorders such as 
depression and schizophrenia[13]. GWAS findings are increasingly being used to better understand 
clinical phenotypes and their boundaries. For example, when SNP effects are combined into composite 
measures of genetic risk[14,15] it has been shown that common polygenic variation for ADHD 
diagnosis confers risk for both ADHD traits and autism-related features in the general population[16] 
and that ASD diagnosis risk is associated with social-communication population trait levels[17]. More 
common gene variants will be identified as sample sizes grow with increased international 
collaborative efforts between research groups[18]. 
It has been known for a long time that genetic syndromes such as Fragile X syndrome and Tuberous 
Sclerosis can manifest as childhood neurodevelopmental disorders. More recently, rare chromosomal 
deletions and duplications (copy number variants, CNVs, <1% population frequency) also have been 
found to contribute to the risk for ADHD[19] ASD and ID[20]. People with neurodevelopmental 
disorders have a higher overall CNV burden than unaffected people as well as higher rates of specific 
pathogenic CNVs including deletions and duplications at chromosome 16p11.2[21] and duplications 
at chromosome 15q13.3[14]. These variants also have pleiotropic effects – for example, the 16p11.2 
microdeletion is associated with developmental delay, cognitive impairment and ASD as well as 
physical manifestations including macrocephaly, obesity and seizures. Several copy number variants 
are highly penetrant for neurodevelopmental disorders (for example approximately 40% of children 
with chromosome 22q11.2 deletions meet the diagnostic criteria for ADHD and around 30% for 
ASD)[22] as well as for affective disorders and psychosis[23]. The relatively high penetrance of these 
neurodevelopmental CNVs for other psychiatric and physical health problems, together with the 
increased availability and reduction in cost of microarray genetic testing platforms in recent years has 
led to much debate about when to refer patients and their families to clinical genetic services for 
testing, with many arguing for a lowering of the threshold. Microarray testing has been recommended 
as a first-line investigation for global developmental delay (GDD) as it has a high diagnostic yield[24], 
particularly when compared with standard karyotyping. Current NICE guidance for ASD only 
recommends referral for genetic testing if dysmorphology, congenital anomalies and/or ID are also 
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present[25] and there are no recommendations made by NICE for testing in ADHD. The diagnostic 
yield seems to be highest when genetic testing is carried out in patients with multiple congenital 
abnormalities and/or dysmorphic features, and genetic testing should be considered even in the 
absence of a significant family history if a de novo mutation is suspected[26]. 
As discussed above, neither common nor rare genetic variants map onto single phenotypes on a one-
to-one basis. This overlap between genetic risk factors for neurodevelopmental disorders is perhaps 
unsurprising given the overlapping clinical features of this spectrum of disorders. In addition, recent 
genetic evidence points to a gradient of psychiatric risk which not only cuts across childhood-onset 
disorders but also across disorders typically considered to be adult-onset, such as schizophrenia[27]. 
Equally, individual neurodevelopmental phenotypes can be viewed as continuously distributed risk 
dimensions[28]. As such, the importance of subthreshold neurodevelopmental symptomatology 
should not be overlooked as it indexes adverse outcomes[29]. Taken together, this evidence argues 
for a more dimensional approach to clinical assessment rather than one constrained by traditional 
diagnostic boundaries.  
In summary, there have been tremendous advances in our understanding of the genetic aetiology of 
neurodevelopmental disorders over the last twenty years. Recognising the contribution of genetic 
factors can be extremely helpful for patients and their families and may help to reduce self-blame and 
stigma, although this needs empirical evidence. Furthermore, understanding the heritability of these 
disorders enables clinicians to have informed discussions with families about the risks for any future 
offspring, both of the index disorder and of other neurodevelopmental conditions - although at 
present these data do not provide personalised risk profiles. Also, genetic risks are probabilistic: not 
all at high genetic risk develop a disorder and not all with a disorder necessarily carry a given risk 
factor. Finally, although relatively rare, increased awareness and appropriate testing for 
neurodevelopmental CNVs is important so that affected individuals can be assessed for associated 
physical and psychiatric manifestations and receive appropriate genetic counselling.  
In this short review, we have focussed on the genetics of neurodevelopmental disorders. However, 
we also acknowledge the important role that environmental factors play in the complex aetiology of 
these conditions. Continued investigation into the interactions between the environment and genetic 
factors will be an important avenue for future research. 
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